Neuronal acetylcholine receptor; alpha6/beta2 · PROTEIN COMPLEX · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Neuronal acetylcholine receptor; alpha6/beta2 shows clinical signal disease relevance led by Alzheimer disease. 2 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P17787. Start with Alzheimer disease, then reuse UniProt P17787 as the stable protein anchor across project notes and exports.
Start with Alzheimer disease, then reuse UniProt P17787 as the stable protein anchor across project notes and exports.
Neuronal acetylcholine receptor; alpha6/beta2 shows clinical signal disease relevance led by Alzheimer disease. 2 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with Alzheimer disease because it currently carries clinical signal support. Linked drugs include POZANICLINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyNeuronal acetylcholine receptor subunit beta-2
Review this target as Neuronal acetylcholine receptor; alpha6/beta2, mapped to UniProt P17787. ChEMBL maps the protein component as Neuronal acetylcholine receptor subunit beta-2. Sequence length is 502 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Neuronal acetylcholine receptor; alpha6/beta2 as ChEMBL target CHEMBL2109237, mapped to UniProt P17787. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Neuronal acetylcholine receptor; alpha6/beta2 is the right protein anchor across sources, using UniProt P17787 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why Alzheimer disease is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Neuronal acetylcholine receptor; alpha6/beta2 |
| Target Type | PROTEIN COMPLEX |
| Organism | Homo sapiens |
| UniProt | P17787 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Neuronal acetylcholine receptor subunit beta-2 |
| UniProt Accession | P17787 |
| Component Type | Protein |
| Sequence Length | 502 aa |
Neuronal acetylcholine receptor subunit beta-2
Review this target as Neuronal acetylcholine receptor; alpha6/beta2, mapped to UniProt P17787. ChEMBL maps the protein component as Neuronal acetylcholine receptor subunit beta-2. Sequence length is 502 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Neuronal acetylcholine receptor; alpha6/beta2 shows clinical signal disease relevance led by Alzheimer disease. 2 more disease programs remain visible in the same review block.
Start review with Alzheimer disease because it currently carries clinical signal support. Linked drugs include POZANICLINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL5412811 | 10.22 | Ki | 0.06 | Preclinical |
| CHEMBL5404069 | 10.11 | Ki | 0.077 | Preclinical |
| CHEMBL594330 | 9.8 | IC50 | 0.16 | Preclinical |
| CHEMBL595286 | 9.59 | IC50 | 0.26 | Preclinical |
| CHEMBL5404578 | 9.44 | Ki | 0.36 | Preclinical |
| CHEMBL595311 | 9.41 | IC50 | 0.39 | Preclinical |
| CHEMBL5438932 | 9.3 | Ki | 0.5 | Preclinical |
| CHEMBL5430462 | 9.17 | Ki | 0.67 | Preclinical |
| CHEMBL5423438 | 9.02 | Ki | 0.95 | Preclinical |
| CHEMBL595047 | 9.02 | IC50 | 0.95 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| protein complex format | 2 | 12 | 9.2 |